LEXX
Lexaria Bioscience Corp.
NASDAQ · Healthcare · Biotechnology · CA
$14.15
+14.85%Year over year
Reported trailing growth
- Revenue
- -68.5%
- EBITDA
- +32.2%
- EBIT
- +31.9%
- EPS
- -46.5%
- Free cash flow
- +23.6%
- Operating cash flow
- +23.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +40.3%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -40.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of May 1, 2026